سعر سانترون 20مجم/10 مل فيال 2026

Mitoxantrone 20 mg/10 ml (2 mg/ml) concentrate for intravenous infusion, 1 vial; anthracenedione cytotoxic agent for hospital oncology/haematology and multiple sclerosis use under specialist supervision.

• Reducing neurologic disability and/or relapse frequency in secondary progressive, progressive relapsing or worsening relapsing-remitting multiple sclerosis (not primary progressive MS).DailyMed (U.S. National Library of Medicine)
• With corticosteroids, initial chemotherapy for pain related to advanced hormone-refractory prostate cancer.DailyMed (U.S. National Library of Medicine)
• In combination with other approved drugs, initial therapy of acute nonlymphocytic leukaemia (ANLL) in adults.DailyMed (U.S. National Library of Medicine)

• Prior hypersensitivity to mitoxantrone.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cardiotoxicity: potentially fatal congestive heart failure may occur during or months to years after therapy; risk increases with cumulative dose. Evaluate LVEF at baseline (and before each dose in MS); do not give to MS patients with LVEF <50% or a clinically significant LVEF reduction.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Secondary acute myeloid leukaemia has occurred in cancer and multiple sclerosis patients treated with mitoxantrone.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Myelosuppression can occur at any dose and is severe at high doses; except in ANLL, generally do not give when baseline neutrophils are below 1,500 cells/mm3.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• May cause fetal harm; considered a potential human teratogen. Women of childbearing potential should avoid pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excreted in human milk (significant concentrations reported for 28 days after the last dose); breastfeeding should be discontinued before starting treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Mitoxantrone (as hydrochloride): Intercalates into DNA, causing cross-links and strand breaks, interferes with RNA and potently inhibits topoisomerase II; cytocidal to proliferating and non-proliferating cells.